<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pyoderma gangrenosum: Pathogenesis, clinical features, and diagnosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pyoderma gangrenosum: Pathogenesis, clinical features, and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pyoderma gangrenosum: Pathogenesis, clinical features, and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Courtney Schadt, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey Callen, MD, FACP, FAAD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 10, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H24503907"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pyoderma gangrenosum (PG) is an uncommon neutrophilic dermatosis that presents as an inflammatory and ulcerative disorder of the skin. In contrast to its name, PG is neither an infectious nor gangrenous condition. The most common presentation of PG is an inflammatory papule or pustule that progresses to a painful ulcer with a violaceous undermined border and a purulent base (<a class="graphic graphic_picture graphicRef83692 graphicRef72260 graphicRef83691 graphicRef52291 graphicRef52528" href="/z/d/graphic/83692.html" rel="external">picture 1A-E</a>). PG may also present with bullous, vegetative, peristomal, and extracutaneous lesions.</p><p>More than half of patients with PG develop the disorder in association with an underlying systemic disease. Inflammatory bowel disease, hematologic disorders, and arthritis represent the most frequent comorbidities.</p><p>A diagnosis of PG rests upon the recognition of consistent clinical and histologic findings and the exclusion of other inflammatory or ulcerative cutaneous disorders. There are no pathognomonic, clinical, or histologic findings of PG.</p><p>The pathogenesis, clinical manifestations, and diagnosis of PG will be discussed here. The treatment and prognosis of PG and other neutrophilic dermatoses are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/83623.html" rel="external">"Pyoderma gangrenosum: Treatment and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/5571.html" rel="external">"Neutrophilic dermatoses"</a>.)</p><p class="headingAnchor" id="H24503914"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>PG is a rare disorder with an estimated incidence of 3 to 10 cases per million people per year [<a href="#rid1">1</a>]. Individuals of any age may be affected, including children [<a href="#rid2">2-4</a>]. PG most commonly develops in young and middle-aged adults, with an average age of onset between 40 and 60 years [<a href="#rid5">5-8</a>]. Between the sexes, women are more frequently affected [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H24503921"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Consistent with its categorization as a neutrophilic dermatosis, PG is characterized by neutrophil-predominant infiltrates in the skin. Research has begun to elucidate dysregulation in the innate and adaptive immune response, in addition to genetic factors, in the pathogenesis of PG:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immune dysregulation </strong>– Studies have revealed complex gene expression profiles in the skin of patients with PG. Lesional skin of PG has increased expression of interleukin (IL) 1-beta, IL-1-alpha, IL-8, IL-12, IL-15, IL-17, IL-23, IL-36, and tumor necrosis factor (TNF)-alpha [<a href="#rid9">9-11</a>]. This upregulation leads to a proinflammatory state through increased activation of inflammasomes, dysregulation of the innate immune system, and recruitment and activation of neutrophils [<a href="#rid9">9</a>]. PG tissue also has increased expression of pattern recognition receptors (PRRs), <em>JAK2</em>, and <em>STAT1</em>, implicating both adaptive and innate immune response dysfunction [<a href="#rid10">10</a>]. The complement pathway, particularly C5a and its role in neutrophil activation, chemotaxis, and inflammatory signaling, may also contribute to the complex pathogenesis of PG [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic factors </strong>– Genetic susceptibility also likely contributes to the development of PG. Familial cases of PG have been reported [<a href="#rid13">13-16</a>]. In addition, PAPA (pyogenic arthritis, pyoderma gangrenosum, and acne) syndrome (OMIM #604416), an autosomal dominant disorder, has been linked to mutations in the <em>PSTPIP1</em>/<em>CD2BP1</em> gene. This mutation leads to decreased inhibition of the inflammasome and, ultimately, increased production of IL-1-beta and autoinflammation [<a href="#rid17">17</a>]. Mutations of the autoinflammatory genes <em>MEFV</em>, <em>NLRP3</em>, <em>NLRP12</em>, <em>NOD2</em>, and <em>LPIN2</em> have been demonstrated in PG, PASH (pyoderma gangrenosum, acne, and suppurative hidradenitis) syndrome, and other inflammatory conditions, including familial Mediterranean fever, cryopyrin-associated periodic syndrome, Crohn disease, and SAPHO (synovitis, acne, pustulosis, hyperostosis, osteitis) syndrome [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/z/d/html/122506.html" rel="external">"Autoinflammatory diseases mediated by inflammasomes and related IL-1 family cytokines (inflammasomopathies)", section on 'PAPA syndrome'</a>.)</p><p></p><p>Further elucidation of the molecular pathways in PG have allowed for more targeted treatments, including TNF-alpha, IL-1, IL-17, IL-23, and IL-6 inhibitors. (See  <a class="medical medical_review" href="/z/d/html/83623.html" rel="external">"Pyoderma gangrenosum: Treatment and prognosis"</a>.)</p><p class="headingAnchor" id="H24503928"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>The clinical manifestations of PG are variable and can be divided into four major subtypes: ulcerative (classic) PG (the most common variant), bullous (atypical) PG, pustular PG, and vegetative PG [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H1537182"><span class="h2">Common features</span><span class="headingEndMark"> — </span>The subtypes of PG share a clinical course characterized by the appearance of an inflammatory papule, pustule, vesicle, or nodule that subsequently expands and breaks down to form an erosion or ulcer. With the exception of vegetative PG, lesion development is often rapid and the level of pain is often greater than expected based upon the appearance of the ulcer [<a href="#rid18">18</a>]. Fever may or may not be present [<a href="#rid19">19</a>].</p><p>Pathergy, a term used to describe the induction or exacerbation of PG in sites of incidental or iatrogenic trauma, is frequently mentioned in descriptions of the clinical behavior of PG. However, not all patients with PG exhibit this feature. Data on the proportion of patients with PG who experience pathergy are limited. In a retrospective study of 103 patients with PG, pathergy was documented in the medical records of 31 percent of patients [<a href="#rid7">7</a>]. In a series of 166 patients with PG, 25 (15 percent) experienced 33 episodes of postsurgical recurrence or exacerbation of the disease; factors associated with increased risk of pathergy included open surgical procedures, Mohs surgery, and PG present at the time of procedure [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H4373563"><span class="h2">Subtypes</span><span class="headingEndMark"> — </span>Descriptions of the major variants of PG are provided below:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ulcerative (classic) pyoderma gangrenosum </strong>– The ulcerative variant of PG represents the vast majority of cases of PG. Ulcerative PG typically begins as a tender, inflammatory papule, pustule, or vesicle that develops on normal-appearing skin or at a site of trauma (<a class="graphic graphic_picture graphicRef59459 graphicRef53733" href="/z/d/graphic/59459.html" rel="external">picture 2A-B</a>). The lower extremities and trunk are the most common sites of involvement, though lesions may occur in other areas [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1">The initial inflammatory lesion subsequently expands peripherally and degenerates centrally, leading to ulcer formation (<a class="graphic graphic_picture graphicRef83692 graphicRef72260 graphicRef83691 graphicRef52291 graphicRef52528" href="/z/d/graphic/83692.html" rel="external">picture 1A-E</a>). The edge of the ulcer usually exhibits a bluish or violaceous color and demonstrates an undermined quality. Irregular expansion of the involved tissue may lead to a serpiginous configuration. The base of the ulcer is purulent and necrotic, and the depth of the ulcer often extends into subcutaneous fat and occasionally reaches the fascia [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1">Patients may have a single lesion or multiple lesions in various stages of development. Ulcers typically resolve with atrophic, cribriform scars.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bullous (atypical) pyoderma gangrenosum </strong>– Bullous PG is a less common, superficial variant of PG that is most commonly seen in patients with PG related to hematologic disease [<a href="#rid6">6</a>]. Unlike ulcerative PG, the arms and face are the most common sites of involvement [<a href="#rid1">1,6</a>]. Patients typically present with the rapid development of blue-gray, inflammatory bullae in the involved areas [<a href="#rid6">6</a>]. The bullae quickly erode, resulting in superficial ulcers (<a class="graphic graphic_picture graphicRef55967" href="/z/d/graphic/55967.html" rel="external">picture 3</a>).</p><p></p><p class="bulletIndent1">Due to the strong association between bullous PG and hematologic disease, patients who present without an associated hematologic disorder should be followed closely for the development of a hematologic disorder [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pustular pyoderma gangrenosum </strong>– Pustular PG usually occurs in patients with inflammatory bowel disease, and tends to arise during periods of acute exacerbations of bowel disease [<a href="#rid18">18</a>]. Affected patients exhibit the rapid development of painful pustules surrounded by erythema (<a class="graphic graphic_picture graphicRef83690" href="/z/d/graphic/83690.html" rel="external">picture 4</a>). Concomitant fever and arthralgias are common [<a href="#rid1">1</a>]. Pyostomatitis vegetans, which presents with multiple small pustules and erosions on the oral mucosa, may be a variant of pustular PG [<a href="#rid1">1,22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vegetative pyoderma gangrenosum </strong>– Vegetative PG (also known as superficial granulomatous pyoderma) is a typically localized, solitary, superficial form of PG that presents as an indolent, mildly painful nodule, plaque, or ulcer (<a class="graphic graphic_picture graphicRef83904" href="/z/d/graphic/83904.html" rel="external">picture 5</a>). A verrucous quality is often present. The undermined borders and purulent bases of ulcerative PG are absent. The head, neck, and trunk are the most common sites for vegetative PG [<a href="#rid1">1</a>].</p><p></p><p class="headingAnchor" id="H4373845"><span class="h2">Special sites</span><span class="headingEndMark"> — </span>In addition to the morphologic subtypes reviewed above, other terms have been used to describe certain presentations of PG. Examples include peristomal PG, genital PG, and extracutaneous PG:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Peristomal pyoderma gangrenosum </strong>–<strong> </strong>Peristomal PG is an uncommon manifestation of PG that is characterized by the development of lesions consistent with ulcerative PG adjacent to a stoma (<a class="graphic graphic_picture graphicRef72285" href="/z/d/graphic/72285.html" rel="external">picture 6</a>). This typically occurs in patients with ulcerative colitis or Crohn’s disease and may develop months to a few decades after placement of a stoma. Trauma caused by maintenance of the stoma or irritation from stoma secretions may play a role in the development of peristomal PG [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genital pyoderma gangrenosum </strong>– Genital PG may involve the vulva, penis, or scrotum. Lesions resemble those of ulcerative PG (<a class="graphic graphic_picture graphicRef83689" href="/z/d/graphic/83689.html" rel="external">picture 7</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extracutaneous pyoderma gangrenosum </strong>– Rarely, PG involves extracutaneous sites. In such cases, sterile neutrophilic infiltration develops in sites such as the lungs, intestine, cornea, liver, spleen, heart, bones, muscle, and central nervous system [<a href="#rid23">23-35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postoperative pyoderma gangrenosum </strong>– Postoperative PG is the development of PG in a surgical site, usually within two weeks after surgery [<a href="#rid36">36</a>]. The initial symptoms are surgical-site erythema and extreme pain out of proportion to the physical examination followed by wound dehiscence or the development of punctate ulcerations that coalesce into larger ulcers. Postoperative PG appears to be more common in women than in men. Common sites of involvement are the breasts and abdomen [<a href="#rid36">36</a>].</p><p></p><p class="headingAnchor" id="H4373281"><span class="h1">ASSOCIATED DISORDERS</span><span class="headingEndMark"> — </span>More than 50 percent of patients with PG have an associated systemic disease, most commonly inflammatory bowel disease, arthritis, and hematologic disease or hematologic malignancy [<a href="#rid5">5-7</a>]. The proportion of patients with specific comorbidities varies among studies [<a href="#rid5">5-7,37</a>]. In one of the largest studies, a retrospective cohort study of 356 adults with PG, 161 (45 percent) had associated comorbidities, including [<a href="#rid37">37</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>146 patients (41 percent) with inflammatory bowel disease</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>73 patients (21 percent) with inflammatory arthritis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>23 patients (7 percent) with solid organ malignant neoplasms</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>21 patients (6 percent) with hematologic malignant neoplasms</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>17 patients (5 percent) with hematologic disorders (monoclonal gammopathy of undetermined significance, myelodysplastic syndrome, or polycythemia vera)</p><p></p><p>Additional findings of this study suggest that patient age influences risk for specific comorbidities. Patients aged 65 years or older were more likely to have associated rheumatoid arthritis, ankylosing spondylitis, solid organ malignant neoplasms, hematologic malignant neoplasms, and hematologic disorders than younger patients. Inflammatory bowel disease was more common in patients under the age of 65 years.</p><p>PG may precede or follow the diagnosis of an associated disorder and may or may not parallel the clinical course of the associated disease [<a href="#rid21">21,38</a>].</p><p>PG may occur as a feature of autoinflammatory syndromes, such as PAPA (pyogenic arthritis, pyoderma gangrenosum, and acne) syndrome, PAPASH (pyogenic arthritis, pyoderma gangrenosum, acne, and suppurative hidradenitis [hidradenitis suppurativa]) syndrome, and PASH (pyoderma gangrenosum, acne, and suppurative hidradenitis) syndrome [<a href="#rid39">39-42</a>]. PAPA syndrome is an autosomal dominant disorder and occurs secondary to a defect in the <em>PSTPIP1</em>/<em>CD2BP1</em> gene. PAPASH syndrome has been described in an adolescent in whom a novel mutation in the <em>PSTPIP1</em> gene was detected [<a href="#rid39">39</a>]. PG has also been described in a patient with dissecting cellulitis of the scalp, hidradenitis suppurativa, and inflammatory acne [<a href="#rid43">43</a>]. (See <a class="local">'Pathogenesis'</a> above and  <a class="medical medical_review" href="/z/d/html/122506.html" rel="external">"Autoinflammatory diseases mediated by inflammasomes and related IL-1 family cytokines (inflammasomopathies)", section on 'PAPA syndrome'</a>.)</p><p>Examples of additional disorders that have been infrequently linked to PG include pulmonary disease, systemic lupus erythematosus, thyroid disease, solid organ cancers, viral and autoimmune hepatitis, sarcoidosis, major depression, and diabetes [<a href="#rid7">7,38,44</a>]. In addition, PG has also been reported in patients exposed to levamisole [<a href="#rid45">45</a>]. Further study is necessary to validate a relationship between these disorders and PG.</p><p class="headingAnchor" id="H24503942"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The clinical, histopathologic, and laboratory findings in PG are nonspecific, and a diagnosis of PG can only be made once other diagnostic possibilities have been excluded. At least a clinical history, physical examination, and skin biopsy should be performed in all patients [<a href="#rid38">38</a>]. In patients known to have diseases associated with PG, the development of an ulcer should raise suspicion for this diagnosis. In addition, once PG has been diagnosed, patients should be evaluated for the presence of an associated underlying disease. (See <a class="local">'Associated disorders'</a> above and <a class="local">'Laboratory studies'</a> below.)</p><p class="headingAnchor" id="H822281"><span class="h2">Diagnostic criteria</span><span class="headingEndMark"> — </span>Historically, universally accepted and validated diagnostic criteria for PG have been lacking. Diagnostic criteria published in 2004 require the exclusion of all other diagnoses, which can be challenging or impractical in the clinical setting (<a class="graphic graphic_table graphicRef117122" href="/z/d/graphic/117122.html" rel="external">table 1</a>) [<a href="#rid46">46</a>]. Newer diagnostic criteria for ulcerative PG developed through a Delphi consensus of international experts provide greater structure to the diagnostic process and are our preferred tool for diagnosis [<a href="#rid47">47</a>]. These criteria include a single major criterion and eight minor criteria, including histologic, history, clinical examination, and treatment findings (<a class="graphic graphic_algorithm graphicRef117120" href="/z/d/graphic/117120.html" rel="external">algorithm 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>Major criterion:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Biopsy of ulcer edge demonstrating a neutrophilic infiltrate</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Minor criteria:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Exclusion of infection</p><p class="bulletIndent2"><span class="glyph">•</span>Pathergy</p><p class="bulletIndent2"><span class="glyph">•</span>Personal history of inflammatory bowel disease or inflammatory arthritis</p><p class="bulletIndent2"><span class="glyph">•</span>History of papule, pustule, or vesicle that rapidly ulcerated</p><p class="bulletIndent2"><span class="glyph">•</span>Peripheral erythema, undermining border, and tenderness at site of ulceration</p><p class="bulletIndent2"><span class="glyph">•</span>Multiple ulcerations (at least one occurring on an anterior lower leg)</p><p class="bulletIndent2"><span class="glyph">•</span>Cribriform or "wrinkled paper" scar(s) at sites of healed ulcers</p><p class="bulletIndent2"><span class="glyph">•</span>Decrease in ulcer size within one month of initiating immunosuppressive medications</p><p></p><p>At least the major criterion and four minor criteria are necessary for diagnosis.</p><p>A third diagnostic criteria, the PARACELSUS score, utilizes a point system with slightly different major and minor criteria [<a href="#rid48">48</a>]. This system was designed specifically for the purpose of differentiating venous leg ulcers from PG.</p><p>Diagnostic criteria are used predominantly for clinical studies but may offer a framework for diagnosis in daily practice.</p><p class="headingAnchor" id="H4373914"><span class="h2">Clinical assessment</span><span class="headingEndMark"> — </span>The clinical assessment of the patient with a lesion suspicious for PG should include a thorough history and physical examination. Patients should be questioned regarding the history of lesion development, associated symptoms, and personal medical history. Examples of findings attainable via a patient history that support a diagnosis of PG include:</p><p class="bulletIndent1"><span class="glyph">●</span>Rapid course of lesion development</p><p class="bulletIndent1"><span class="glyph">●</span>Initial lesion consistent with papule, pustule, or vesicle</p><p class="bulletIndent1"><span class="glyph">●</span>Pain out of proportion to lesion</p><p class="bulletIndent1"><span class="glyph">●</span>History of preceding trauma (pathergy)</p><p class="bulletIndent1"><span class="glyph">●</span>History of disorders associated with PG (see <a class="local">'Associated disorders'</a> above)</p><p></p><p>The physical examination is useful for identifying the extent of disease, narrowing the differential diagnosis, and detecting clinical signs of PG-associated disorders.</p><p class="headingAnchor" id="H4373900"><span class="h2">Biopsy</span><span class="headingEndMark"> — </span>Since the histopathologic findings of PG are nonspecific, biopsies are most useful for excluding other disorders that may present with similar clinical findings. A biopsy is indicated in patients without a preceding history of PG and in patients with established PG who present with lesions with atypical features or lesions that fail to respond as expected to therapy. Although clinicians are often concerned about biopsy-induced pathergy, the need to rule out other disorders and ensure proper treatment supersedes concern for the induction of an exacerbation of PG.</p><p class="headingAnchor" id="H603219"><span class="h3">Procedure</span><span class="headingEndMark"> — </span>The optimal procedure for biopsy is an elliptical incisional biopsy that incorporates both the inflamed lesion border and ulcer edge and extends vertically into the subcutaneous fat [<a href="#rid46">46</a>]. A tissue specimen that includes the inflamed border should be sent for routine histopathologic examination and microbial stains. In addition, a specimen from the ulcer should be sent for culture to evaluate for bacterial, fungal, and atypical mycobacterial infections.</p><p class="headingAnchor" id="H603233"><span class="h3">Pathology</span><span class="headingEndMark"> — </span>Specimens taken from the earliest lesions of PG demonstrate perifollicular inflammation and intradermal abscess formation (<a class="graphic graphic_picture graphicRef55462 graphicRef79287" href="/z/d/graphic/55462.html" rel="external">picture 8A-B</a>) [<a href="#rid49">49</a>]. Once lesions progress to ulceration, epidermal and superficial dermal necrosis with an underlying mixed inflammatory cell infiltrate and abscess formation are typically detected. Giant cells may be found, and tissue from the edge of the lesion may demonstrate vascular changes suggestive of lymphocytic vasculitis. Leukocytoclastic vasculitis may also be present [<a href="#rid49">49</a>].</p><p>Additional findings may be identified based upon the subtype of PG. Specimens from bullous PG demonstrate subepidermal bullae. Pseudoepitheliomatous hyperplasia, sinus tracts, and palisading granulomas are features consistent with vegetative PG.</p><p>Direct immunofluorescence studies yield nonspecific findings in PG. Deposition of IgM, C3, and fibrin in vessel walls may be detected [<a href="#rid38">38</a>]. Because of the nonspecific nature of the results, direct immunofluorescence is usually only conducted when additional clinical findings indicate a need to exclude autoimmune bullous disease, lupus, or vasculitis as a cause of ulceration [<a href="#rid46">46</a>]. (See  <a class="medical medical_review" href="/z/d/html/13684.html" rel="external">"Approach to the patient with cutaneous blisters", section on 'Direct immunofluorescence'</a>.)</p><p class="headingAnchor" id="H4373929"><span class="h2">Laboratory studies</span><span class="headingEndMark"> — </span>Similar to tissue biopsies, there are no laboratory studies that provide a definitive diagnosis of PG. Nonspecific findings such as leukocytosis, elevation of the erythrocyte sedimentation rate, and elevation of C-reactive protein levels may be present [<a href="#rid19">19</a>].</p><p>Laboratory tests are most useful for narrowing the differential diagnosis and identifying the presence of PG-associated diseases. Recommendations for the work-up of these patients vary. We typically obtain the following studies in patients with clinical and histopathologic findings consistent with PG:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complete blood count</strong> (to evaluate for underlying hematologic disorders)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Comprehensive metabolic panel</strong> (to evaluate for hepatic or renal dysfunction and glucose abnormalities prior to initiation of systemic glucocorticoids or immunosuppressive agents) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antinuclear antibody titer</strong> (to evaluate for the presence of systemic lupus erythematosus or collagen vascular disorders in association with PG)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antineutrophilic cytoplasmic antibodies</strong> (to evaluate for granulomatous vasculitis as a cause of ulceration)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypercoagulability studies </strong>(antiphospholipid antibody screen to evaluate for antiphospholipid syndrome as a cause of ulceration; based upon clinical suspicion, other tests to evaluate for thrombotic states [eg, cryoglobulins, Factor V Leiden, methylene tetrahydrofolate reductase])</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hepatitis panel</strong> (to evaluate for associated hepatitis B or C, particularly for patients in whom immunomodulatory therapy is considered)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rheumatoid factor</strong> (as a component of the evaluation for cryoglobulinemia and rheumatoid arthritis) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serum immunofixation electrophoresis</strong> (to evaluate for paraproteins)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chest radiography</strong> (to evaluate for presence of extracutaneous involvement and for possible infection prior to the initiation of immunosuppressive therapy)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Colonoscopy</strong> (to evaluate for underlying inflammatory bowel disease unless another cause of PG is identified)</p><p></p><p>Additional tests to evaluate for associated disorders and disorders in the differential diagnosis are ordered based upon clinical suspicion for specific diseases.</p><p class="headingAnchor" id="H4374004"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>Due to the lack of a definitive test for PG, misdiagnosis can occur. In one retrospective study, 15 of 157 consecutive patients seen at an academic institution and given a diagnosis of PG (10 percent) were subsequently found to have an alternative diagnosis [<a href="#rid50">50</a>].</p><p>Vascular occlusion disorders, venous disease, vasculitis, malignancy, cutaneous infection, drugs, exogenous tissue injury, and ulcerative inflammatory disorders (eg, cutaneous Crohn’s disease and ulcerative necrobiosis lipoidica) may be mistaken for PG (<a class="graphic graphic_table graphicRef72103" href="/z/d/graphic/72103.html" rel="external">table 2</a>) [<a href="#rid50">50</a>]. Antiphospholipid-antibody syndrome is one of the most common disorders mistaken for PG; other more commonly confused disorders include venous stasis ulcers, granulomatosis with polyangiitis, factitial ulcers, sporotrichosis, polyarteritis nodosa, livedoid vasculopathy, angiocentric T cell lymphoma, and cryoglobulinemia [<a href="#rid50">50</a>]. Necrotizing fasciitis is an additional potential misdiagnosis [<a href="#rid51">51</a>]. Aggressive debridement for this presumed diagnosis can lead to significant morbidity and deformity [<a href="#rid52">52-54</a>]. (See  <a class="medical medical_review" href="/z/d/html/5571.html" rel="external">"Neutrophilic dermatoses", section on 'Necrotizing neutrophilic dermatoses'</a> and  <a class="medical medical_review" href="/z/d/html/7662.html" rel="external">"Necrotizing soft tissue infections"</a>.)</p><p>The clinical history, biopsy, and directed laboratory studies attained during patient evaluation aid in distinguishing PG from other diseases. Reassessment of a diagnosis of PG is indicated if the disease fails to respond as expected to therapy. (See  <a class="medical medical_review" href="/z/d/html/83623.html" rel="external">"Pyoderma gangrenosum: Treatment and prognosis"</a>.)</p><p class="headingAnchor" id="H131144110"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/121552.html" rel="external">"Society guideline links: Pyoderma gangrenosum"</a>.)</p><p class="headingAnchor" id="H15016105"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/85634.html" rel="external">"Patient education: Pyoderma gangrenosum (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H603259"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Pyoderma gangrenosum is an uncommon neutrophilic dermatosis that most commonly presents with inflammatory ulcers on the skin. Although PG may occur at any age, there is a predilection for young and middle-aged adults and women. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – The factors that contribute to the development of PG are not well understood. Factors that are postulated to contribute to PG include dysregulation of the immune system and genetic susceptibility. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – The clinical manifestations of PG vary. The most common presentation is ulcerative (classic) PG, which typically presents as a rapidly developing, painful purulent ulcer with a violaceous and undermined border (<a class="graphic graphic_picture graphicRef83692 graphicRef72260 graphicRef83691 graphicRef52291 graphicRef52528" href="/z/d/graphic/83692.html" rel="external">picture 1A-E</a>). Other variants of PG include bullous, pustular, and vegetative presentations. PG may also develop in peristomal, genital, and extracutaneous locations. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Associated disorders</strong> – More than 50 percent of patients with PG have an associated systemic disease. The strongest associations are between PG and inflammatory bowel disease, hematologic disorders, and arthritis. (See <a class="local">'Associated disorders'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Since the clinical and histologic findings of PG are nonspecific, PG is a diagnosis of exclusion (<a class="graphic graphic_table graphicRef72103" href="/z/d/graphic/72103.html" rel="external">table 2</a>). At a minimum, the patient evaluation should include a patient history, physical examination, and biopsy to detect findings consistent with PG and to rule out other diseases. (See <a class="local">'Diagnosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ruocco E, Sangiuliano S, Gravina AG, et al. Pyoderma gangrenosum: an updated review. J Eur Acad Dermatol Venereol 2009; 23:1008.</a></li><li><a class="nounderline abstract_t">Allen CP, Hull J, Wilkison N, Burge SM. Pediatric pyoderma gangrenosum with splenic and pulmonary involvement. Pediatr Dermatol 2013; 30:497.</a></li><li><a class="nounderline abstract_t">Bhat RM, Shetty SS, Kamath GH. Pyoderma Gangrenosum in childhood. Int J Dermatol 2004; 43:205.</a></li><li><a class="nounderline abstract_t">Torrelo A, Colmenero I, Serrano C, et al. Pyoderma gangrenosum in an infant. Pediatr Dermatol 2006; 23:338.</a></li><li><a class="nounderline abstract_t">von den Driesch P. Pyoderma gangrenosum: a report of 44 cases with follow-up. Br J Dermatol 1997; 137:1000.</a></li><li><a class="nounderline abstract_t">Bennett ML, Jackson JM, Jorizzo JL, et al. Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine (Baltimore) 2000; 79:37.</a></li><li><a class="nounderline abstract_t">Binus AM, Qureshi AA, Li VW, Winterfield LS. Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients. Br J Dermatol 2011; 165:1244.</a></li><li><a class="nounderline abstract_t">Saracino A, Kelly R, Liew D, Chong A. Pyoderma gangrenosum requiring inpatient management: a report of 26 cases with follow up. Australas J Dermatol 2011; 52:218.</a></li><li><a class="nounderline abstract_t">Marzano AV, Damiani G, Ceccherini I, et al. Autoinflammation in pyoderma gangrenosum and its syndromic form (pyoderma gangrenosum, acne and suppurative hidradenitis). Br J Dermatol 2017; 176:1588.</a></li><li><a class="nounderline abstract_t">Ortega-Loayza AG, Nugent WH, Lucero OM, et al. Dysregulation of inflammatory gene expression in lesional and nonlesional skin of patients with pyoderma gangrenosum. Br J Dermatol 2018; 178:e35.</a></li><li><a class="nounderline abstract_t">Ortega-Loayza AG, Friedman MA, Reese AM, et al. Molecular and Cellular Characterization of Pyoderma Gangrenosum: Implications for the Use of Gene Expression. J Invest Dermatol 2022; 142:1217.</a></li><li><a class="nounderline abstract_t">Lu JD, Milakovic M, Ortega-Loayza AG, et al. Pyoderma gangrenosum: proposed pathogenesis and current use of biologics with an emphasis on complement C5a inhibitor IFX-1. Expert Opin Investig Drugs 2020; 29:1179.</a></li><li><a class="nounderline abstract_t">Alberts JH, Sams HH, Miller JL, King LE Jr. Familial ulcerative pyoderma gangrenosum: a report of 2 kindred. Cutis 2002; 69:427.</a></li><li><a class="nounderline abstract_t">Khandpur S, Mehta S, Reddy BS. Pyoderma gangrenosum in two siblings: a familial predisposition. Pediatr Dermatol 2001; 18:308.</a></li><li><a class="nounderline abstract_t">al-Rimawi HS, Abuekteish FM, Daoud AS, Oboosi MM. Familial pyoderma gangrenosum presenting in infancy. Eur J Pediatr 1996; 155:759.</a></li><li><a class="nounderline abstract_t">Shands JW Jr, Flowers FP, Hill HM, Smith JO. Pyoderma gangrenosum in a kindred. Precipitation by surgery or mild physical trauma. J Am Acad Dermatol 1987; 16:931.</a></li><li><a class="nounderline abstract_t">Yeon HB, Lindor NM, Seidman JG, Seidman CE. Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome maps to chromosome 15q. Am J Hum Genet 2000; 66:1443.</a></li><li class="breakAll">Powell FC, Hackett BC, Wallach D. Pyoderma gangrenosum. In: Fitzpatrick's Dermatology in General Medicine, 8th ed, Goldsmith LA, Katz SI, Gilchrest BA, et al (Eds), McGraw-Hill Companies, Inc., 2012. Vol 1, p.371.</li><li><a class="nounderline abstract_t">Wong WW, Machado GR, Hill ME. Pyoderma gangrenosum: the great pretender and a challenging diagnosis. J Cutan Med Surg 2011; 15:322.</a></li><li><a class="nounderline abstract_t">Xia FD, Liu K, Lockwood S, et al. Risk of developing pyoderma gangrenosum after procedures in patients with a known history of pyoderma gangrenosum-A retrospective analysis. J Am Acad Dermatol 2018; 78:310.</a></li><li><a class="nounderline abstract_t">Callen JP, Jackson JM. Pyoderma gangrenosum: an update. Rheum Dis Clin North Am 2007; 33:787.</a></li><li><a class="nounderline abstract_t">Nico MM, Hussein TP, Aoki V, Lourenço SV. Pyostomatitis vegetans and its relation to inflammatory bowel disease, pyoderma gangrenosum, pyodermatitis vegetans, and pemphigus. J Oral Pathol Med 2012; 41:584.</a></li><li><a class="nounderline abstract_t">Brown TS, Marshall GS, Callen JP. Cavitating pulmonary infiltrate in an adolescent with pyoderma gangrenosum: a rarely recognized extracutaneous manifestation of a neutrophilic dermatosis. J Am Acad Dermatol 2000; 43:108.</a></li><li><a class="nounderline abstract_t">Fukuhara K, Urano Y, Kimura S, et al. Pyoderma gangrenosum with rheumatoid arthritis and pulmonary aseptic abscess responding to treatment with dapsone. Br J Dermatol 1998; 139:556.</a></li><li><a class="nounderline abstract_t">Abdelrazeq AS, Lund JN, Leveson SH. Pouchitis-associated pyoderma gangrenosum following restorative proctocolectomy for ulcerative colitis. Eur J Gastroenterol Hepatol 2004; 16:1057.</a></li><li><a class="nounderline abstract_t">Nurre LD, Rabalais GP, Callen JP. Neutrophilic dermatosis-associated sterile chronic multifocal osteomyelitis in pediatric patients: case report and review. Pediatr Dermatol 1999; 16:214.</a></li><li><a class="nounderline abstract_t">East-Innis A, Desnoes R, Thame K, et al. Pyoderma gangrenosum associated with osteomyelitis in a paediatric patient: a case report. West Indian Med J 2005; 54:207.</a></li><li><a class="nounderline abstract_t">Goldshmid O, Dovorish Z, Zehavi T, et al. Coexistent pyoderma gangrenosum and tibialis anterior myositis as presenting manifestations of Crohn's disease: case report and review of the literature. Rheumatol Int 2011; 31:525.</a></li><li><a class="nounderline abstract_t">Wilson DM, John GR, Callen JP. Peripheral ulcerative keratitis--an extracutaneous neutrophilic disorder: report of a patient with rheumatoid arthritis, pustular vasculitis, pyoderma gangrenosum, and Sweet's syndrome with an excellent response to cyclosporine therapy. J Am Acad Dermatol 1999; 40:331.</a></li><li><a class="nounderline abstract_t">Brown BA, Parker CT, Bower KS. Effective steroid-sparing treatment for peripheral ulcerative keratitis and pyoderma gangrenosum. Cornea 2001; 20:117.</a></li><li><a class="nounderline abstract_t">Teasley LA, Foster CS, Baltatzis S. Sclerokeratitis and facial skin lesions: a case report of pyoderma gangrenosum and its response to dapsone therapy. Cornea 2007; 26:215.</a></li><li><a class="nounderline abstract_t">Vadillo M, Jucgla A, Podzamczer D, et al. Pyoderma gangrenosum with liver, spleen and bone involvement in a patient with chronic myelomonocytic leukaemia. Br J Dermatol 1999; 141:541.</a></li><li><a class="nounderline abstract_t">Chanson P, Timsit J, Kujas M, et al. Pituitary granuloma and pyoderma gangrenosum. J Endocrinol Invest 1990; 13:677.</a></li><li><a class="nounderline abstract_t">Koester G, Tarnower A, Levisohn D, Burgdorf W. Bullous pyoderma gangrenosum. J Am Acad Dermatol 1993; 29:875.</a></li><li><a class="nounderline abstract_t">Scherlinger M, Guillet S, Doutre MS, et al. Pyoderma gangrenosum with extensive pulmonary involvement. J Eur Acad Dermatol Venereol 2017; 31:e214.</a></li><li><a class="nounderline abstract_t">Tolkachjov SN, Fahy AS, Wetter DA, et al. Postoperative pyoderma gangrenosum (PG): the Mayo Clinic experience of 20 years from 1994 through 2014. J Am Acad Dermatol 2015; 73:615.</a></li><li><a class="nounderline abstract_t">Ashchyan HJ, Butler DC, Nelson CA, et al. The Association of Age With Clinical Presentation and Comorbidities of Pyoderma Gangrenosum. JAMA Dermatol 2018; 154:409.</a></li><li><a class="nounderline abstract_t">Ahronowitz I, Harp J, Shinkai K. Etiology and management of pyoderma gangrenosum: a comprehensive review. Am J Clin Dermatol 2012; 13:191.</a></li><li><a class="nounderline abstract_t">Marzano AV, Trevisan V, Gattorno M, et al. Pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH): a new autoinflammatory syndrome associated with a novel mutation of the PSTPIP1 gene. JAMA Dermatol 2013; 149:762.</a></li><li><a class="nounderline abstract_t">Braun-Falco M, Kovnerystyy O, Lohse P, Ruzicka T. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)--a new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol 2012; 66:409.</a></li><li><a class="nounderline abstract_t">Marzano AV, Ishak RS, Colombo A, et al. Pyoderma gangrenosum, acne and suppurative hidradenitis syndrome following bowel bypass surgery. Dermatology 2012; 225:215.</a></li><li><a class="nounderline abstract_t">Marzano AV, Ceccherini I, Gattorno M, et al. Association of pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) shares genetic and cytokine profiles with other autoinflammatory diseases. Medicine (Baltimore) 2014; 93:e187.</a></li><li><a class="nounderline abstract_t">Koshelev MV, Garrison PA, Wright TS. Concurrent hidradenitis suppurativa, inflammatory acne, dissecting cellulitis of the scalp, and pyoderma gangrenosum in a 16-year-old boy. Pediatr Dermatol 2014; 31:e20.</a></li><li><a class="nounderline abstract_t">Al Ghazal P, Herberger K, Schaller J, et al. Associated factors and comorbidities in patients with pyoderma gangrenosum in Germany: a retrospective multicentric analysis in 259 patients. Orphanet J Rare Dis 2013; 8:136.</a></li><li><a class="nounderline abstract_t">Jeong HS, Layher H, Cao L, et al. Pyoderma gangrenosum (PG) associated with levamisole-adulterated cocaine: Clinical, serologic, and histopathologic findings in a cohort of patients. J Am Acad Dermatol 2016; 74:892.</a></li><li><a class="nounderline abstract_t">Su WP, Davis MD, Weenig RH, et al. Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol 2004; 43:790.</a></li><li><a class="nounderline abstract_t">Maverakis E, Ma C, Shinkai K, et al. Diagnostic Criteria of Ulcerative Pyoderma Gangrenosum: A Delphi Consensus of International Experts. JAMA Dermatol 2018; 154:461.</a></li><li><a class="nounderline abstract_t">Jockenhöfer F, Wollina U, Salva KA, et al. The PARACELSUS score: a novel diagnostic tool for pyoderma gangrenosum. Br J Dermatol 2019; 180:615.</a></li><li class="breakAll">Weedon D. The vasculopathic reaction pattern. In: Weedon's Skin Pathology, 3rd ed, Elsevier Limited, 2010. p.195.</li><li><a class="nounderline abstract_t">Weenig RH, Davis MD, Dahl PR, Su WP. Skin ulcers misdiagnosed as pyoderma gangrenosum. N Engl J Med 2002; 347:1412.</a></li><li><a class="nounderline abstract_t">Sanchez IM, Lowenstein S, Johnson KA, et al. Clinical Features of Neutrophilic Dermatosis Variants Resembling Necrotizing Fasciitis. JAMA Dermatol 2019; 155:79.</a></li><li><a class="nounderline abstract_t">Touil LL, Gurusinghe DA, Sadri A, et al. Postsurgical Pyoderma Gangrenosum Versus Necrotizing Fasciitis: Can We Spot the Difference? Ann Plast Surg 2017; 78:582.</a></li><li><a class="nounderline abstract_t">Hradil E, Jeppsson C, Hamnerius N, Svensson Å. The diagnosis you wish you had never operated on: Pyoderma gangrenosum misdiagnosed as necrotizing fasciitis-a case report. Acta Orthop 2017; 88:231.</a></li><li><a class="nounderline abstract_t">Berger N, Ebenhoch M, Salzmann M. Postoperative Pyoderma Gangrenosum in Children: The Case Report of a 13-Year-Old Boy With Pyoderma Gangrenosum After Hip Reconstruction Surgery and a Review of the Literature. J Pediatr Orthop 2017; 37:e379.</a></li></ol></div><div id="topicVersionRevision">Topic 13782 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19470075" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pyoderma gangrenosum: an updated review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23627664" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pediatric pyoderma gangrenosum with splenic and pulmonary involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15009393" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pyoderma Gangrenosum in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16918628" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Pyoderma gangrenosum in an infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9470924" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Pyoderma gangrenosum: a report of 44 cases with follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10670408" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21824126" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21834821" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Pyoderma gangrenosum requiring inpatient management: a report of 26 cases with follow up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27943240" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Autoinflammation in pyoderma gangrenosum and its syndromic form (pyoderma gangrenosum, acne and suppurative hidradenitis).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28734003" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Dysregulation of inflammatory gene expression in lesional and nonlesional skin of patients with pyoderma gangrenosum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34536481" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Molecular and Cellular Characterization of Pyoderma Gangrenosum: Implications for the Use of Gene Expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32880206" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pyoderma gangrenosum: proposed pathogenesis and current use of biologics with an emphasis on complement C5a inhibitor IFX-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12078842" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Familial ulcerative pyoderma gangrenosum: a report of 2 kindred.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11576404" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Pyoderma gangrenosum in two siblings: a familial predisposition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8874107" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Familial pyoderma gangrenosum presenting in infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3584575" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Pyoderma gangrenosum in a kindred. Precipitation by surgery or mild physical trauma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10729114" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome maps to chromosome 15q.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10729114" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome maps to chromosome 15q.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22202507" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pyoderma gangrenosum: the great pretender and a challenging diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28947285" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Risk of developing pyoderma gangrenosum after procedures in patients with a known history of pyoderma gangrenosum-A retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18037117" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Pyoderma gangrenosum: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22563766" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Pyostomatitis vegetans and its relation to inflammatory bowel disease, pyoderma gangrenosum, pyodermatitis vegetans, and pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10863234" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Cavitating pulmonary infiltrate in an adolescent with pyoderma gangrenosum: a rarely recognized extracutaneous manifestation of a neutrophilic dermatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9767321" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Pyoderma gangrenosum with rheumatoid arthritis and pulmonary aseptic abscess responding to treatment with dapsone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15371932" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Pouchitis-associated pyoderma gangrenosum following restorative proctocolectomy for ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10383779" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Neutrophilic dermatosis-associated sterile chronic multifocal osteomyelitis in pediatric patients: case report and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16209228" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Pyoderma gangrenosum associated with osteomyelitis in a paediatric patient: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19847433" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Coexistent pyoderma gangrenosum and tibialis anterior myositis as presenting manifestations of Crohn's disease: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10025862" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Peripheral ulcerative keratitis--an extracutaneous neutrophilic disorder: report of a patient with rheumatoid arthritis, pustular vasculitis, pyoderma gangrenosum, and Sweet's syndrome with an excellent response to cyclosporine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11188994" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Effective steroid-sparing treatment for peripheral ulcerative keratitis and pyoderma gangrenosum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17251816" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Sclerokeratitis and facial skin lesions: a case report of pyoderma gangrenosum and its response to dapsone therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10583064" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Pyoderma gangrenosum with liver, spleen and bone involvement in a patient with chronic myelomonocytic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2273210" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Pituitary granuloma and pyoderma gangrenosum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8408832" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Bullous pyoderma gangrenosum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27658239" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Pyoderma gangrenosum with extensive pulmonary involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26209218" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Postoperative pyoderma gangrenosum (PG): the Mayo Clinic experience of 20 years from 1994 through 2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29450453" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The Association of Age With Clinical Presentation and Comorbidities of Pyoderma Gangrenosum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22356259" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Etiology and management of pyoderma gangrenosum: a comprehensive review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23571383" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH): a new autoinflammatory syndrome associated with a novel mutation of the PSTPIP1 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21745697" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)--a new autoinflammatory syndrome distinct from PAPA syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23171584" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Pyoderma gangrenosum, acne and suppurative hidradenitis syndrome following bowel bypass surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25501066" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Association of pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) shares genetic and cytokine profiles with other autoinflammatory diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24118007" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Concurrent hidradenitis suppurativa, inflammatory acne, dissecting cellulitis of the scalp, and pyoderma gangrenosum in a 16-year-old boy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24010984" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Associated factors and comorbidities in patients with pyoderma gangrenosum in Germany: a retrospective multicentric analysis in 259 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26785804" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Pyoderma gangrenosum (PG) associated with levamisole-adulterated cocaine: Clinical, serologic, and histopathologic findings in a cohort of patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15533059" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29450466" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Diagnostic Criteria of Ulcerative Pyoderma Gangrenosum: A Delphi Consensus of International Experts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29388188" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The PARACELSUS score: a novel diagnostic tool for pyoderma gangrenosum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29388188" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The PARACELSUS score: a novel diagnostic tool for pyoderma gangrenosum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12409543" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Skin ulcers misdiagnosed as pyoderma gangrenosum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30383110" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Clinical Features of Neutrophilic Dermatosis Variants Resembling Necrotizing Fasciitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28379857" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Postsurgical Pyoderma Gangrenosum Versus Necrotizing Fasciitis: Can We Spot the Difference?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27875063" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The diagnosis you wish you had never operated on: Pyoderma gangrenosum misdiagnosed as necrotizing fasciitis-a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28719544" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Postoperative Pyoderma Gangrenosum in Children: The Case Report of a 13-Year-Old Boy With Pyoderma Gangrenosum After Hip Reconstruction Surgery and a Review of the Literature.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
